secwatch.observer — SEC 8-K summary
======================================

Issuer:     Harvard Apparatus Regenerative Technology, Inc. (HRGN)
CIK:        0001563665
Form:       8-K
Filed at:   2022-01-27T23:59:59+00:00
Accession:  0001104659-22-008048
Event type: litigation
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biostage wins court order requiring insurer to pay legal defense; to host investor webinar Jan 27
--------------------------------------------------------------------------------

- Court ordered Medmarc to continue paying Biostage's legal defense in a wrongful death suit over a tracheal implant, finding Medmarc breached its duty and awarding attorneys' fees.
- Biostage discontinued tracheal implant development and now focuses on esophageal implant, which has FDA approval for a clinical trial.
- Interim CEO David Green will host webinars on Jan 27 to discuss the clinical trial, capital raising, and NASDAQ uplisting.
- A second webinar is scheduled for Jan 27 at 8pm ET / Jan 28 9am Beijing time for investor Q&A.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1563665/000110465922008048/0001104659-22-008048-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1563665/000110465922008048/tm224636d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-008048

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer